| Megan Lenkersdorfer, NP | |
|
1055 N Curtis Rd, Boise, ID 83706-1309 | |
| (208) 367-2121 | |
| Not Available |
| Full Name | Megan Lenkersdorfer |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 13 Years |
| Location | 1055 N Curtis Rd, Boise, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477197036 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 62697 (Idaho) | Secondary |
| 363L00000X | Nurse Practitioner | 62697 (Idaho) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medical Directors Of Idaho Pllc | 1951628544 | 14 |
News Archive
Led by Prof. Mohamed Lamkanfi (VIB-Ghent University), researchers have demonstrated in animal models that a protein called NLRP2 plays an important role in early embryogenesis, the process of cell division in fertilized eggs that occurs before they implant into the lining of the uterus.
A growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome, according to a pilot study conducted at the Icahn School of Medicine at Mount Sinai and published yesterday on Pub Med, a public database of biomedical topics maintained by the National Institutes of Health (study originally published in the December 12 issue of the journal Molecular Autism).
A selection of health policy stories from Pennsylvania, Virginia, California, Louisiana, Texas, Kansas and Georgia.
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.
› Verified 6 days ago
| Entity Name | Saint Alphonsus Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649357716 PECOS PAC ID: 3476462359 Enrollment ID: O20040204001036 |
News Archive
Led by Prof. Mohamed Lamkanfi (VIB-Ghent University), researchers have demonstrated in animal models that a protein called NLRP2 plays an important role in early embryogenesis, the process of cell division in fertilized eggs that occurs before they implant into the lining of the uterus.
A growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome, according to a pilot study conducted at the Icahn School of Medicine at Mount Sinai and published yesterday on Pub Med, a public database of biomedical topics maintained by the National Institutes of Health (study originally published in the December 12 issue of the journal Molecular Autism).
A selection of health policy stories from Pennsylvania, Virginia, California, Louisiana, Texas, Kansas and Georgia.
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.
› Verified 6 days ago
| Entity Name | Medical Directors Of Idaho Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710392410 PECOS PAC ID: 1951628544 Enrollment ID: O20150319000233 |
News Archive
Led by Prof. Mohamed Lamkanfi (VIB-Ghent University), researchers have demonstrated in animal models that a protein called NLRP2 plays an important role in early embryogenesis, the process of cell division in fertilized eggs that occurs before they implant into the lining of the uterus.
A growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome, according to a pilot study conducted at the Icahn School of Medicine at Mount Sinai and published yesterday on Pub Med, a public database of biomedical topics maintained by the National Institutes of Health (study originally published in the December 12 issue of the journal Molecular Autism).
A selection of health policy stories from Pennsylvania, Virginia, California, Louisiana, Texas, Kansas and Georgia.
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan Lenkersdorfer, NP 3340 E Goldstone Dr, Meridian, ID 83642 Ph: (208) 367-7350 | Megan Lenkersdorfer, NP 1055 N Curtis Rd, Boise, ID 83706-1309 Ph: (208) 367-2121 |
News Archive
Led by Prof. Mohamed Lamkanfi (VIB-Ghent University), researchers have demonstrated in animal models that a protein called NLRP2 plays an important role in early embryogenesis, the process of cell division in fertilized eggs that occurs before they implant into the lining of the uterus.
A growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome, according to a pilot study conducted at the Icahn School of Medicine at Mount Sinai and published yesterday on Pub Med, a public database of biomedical topics maintained by the National Institutes of Health (study originally published in the December 12 issue of the journal Molecular Autism).
A selection of health policy stories from Pennsylvania, Virginia, California, Louisiana, Texas, Kansas and Georgia.
Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent.
› Verified 6 days ago